Integra LifeSciences Holdings Corporation (IART) 10-Year Financial Performance & Capital Metrics

IART • • Industrial / General

HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems

AboutIntegra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.Show more

Revenue $1.61B +4.5%
EBITDA $169M -28.1%
Net Income -$7M -110.3%
EPS (Diluted) -0.09 -110.7%
Gross Margin 54.77% -4.6%
EBITDA Margin 10.49% -31.2%
Operating Margin 1.76% -75.6%
Net Margin -0.43% -109.8%
ROE -0.44% -111.1%
ROIC 0.68% -75.8%
Debt/Equity 1.28 +21.3%
Interest Coverage 0.40 -81.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 4.1% through buybacks
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak 3Y average ROE of 4.6%
✗Weak Piotroski F-Score: 3/9
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.66%

5Y1.2%

3Y1.45%

TTM4.99%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-7469.3%

EPS CAGR

10Y-

5Y-

3Y-

TTM-6928.63%

ROCE

10Y Avg4.29%

5Y Avg4.33%

3Y Avg3.61%

Latest0.86%

Peer Comparison

Surgical Energy & Ablation Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BDMDBaird Medical Investment Holdings Limited	45.91M	1.25	2.55	17.74%	33.62%	33%	0.53
IVFINVO Fertility, Inc.	12.29M	0.81	-0.03	116.25%	-417.01%	-495.09%	0.78
AEMDAethlon Medical, Inc.	2.64M	2.71	-0.03			-0.2%	0.13
HYPDHyperion DeFi, Inc.	27.38M	3.35	-0.06	14.14%	-73.86%	-36.05%
NAOVNanoVibronix, Inc.	1.59M	1.46	-0.11	12.05%	-133.04%	-8.41%	0.19
ALURAllurion Technologies Inc.	23.21M	1.89	-0.16	-39.94%	-251.56%
RBOTVicarious Surgical Inc.	18.48M	2.86	-0.27			-380.42%	0.30
TELATELA Bio, Inc.	44.09M	0.99	-0.74	18.56%	-50.61%	-25.05%	1.51

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	882.73M	992.08M	1.19B	1.47B	1.52B	1.37B	1.54B	1.56B	1.54B	1.61B
Revenue Growth %	-0.05%	0.12%	0.2%	0.24%	0.03%	-0.1%	0.12%	0.01%	-0.01%	0.04%
Cost of Goods Sold+	326.54M	349.09M	435.51M	571.5M	564.68M	520.83M	597.81M	587.36M	656.84M	728.47M
COGS % of Revenue	0.37%	0.35%	0.37%	0.39%	0.37%	0.38%	0.39%	0.38%	0.43%	0.45%
Gross Profit+	556.19M	642.99M	752.73M	900.95M	952.88M	851.03M	944.64M	970.31M	884.74M	882.06M
Gross Margin %	0.63%	0.65%	0.63%	0.61%	0.63%	0.62%	0.61%	0.62%	0.57%	0.55%
Gross Profit Growth %	-0.03%	0.16%	0.17%	0.2%	0.06%	-0.11%	0.11%	0.03%	-0.09%	-0%
Operating Expenses+	476.61M	527.65M	707.92M	789.95M	859.12M	699.66M	747.41M	731.39M	773.21M	853.65M
OpEx % of Revenue	0.54%	0.53%	0.6%	0.54%	0.57%	0.51%	0.48%	0.47%	0.5%	0.53%
Selling, General & Admin	415.76M	455.63M	624.1M	690.75M	687.6M	594.53M	637.45M	616.32M	656.64M	716.98M
SG&A % of Revenue	0.47%	0.46%	0.53%	0.47%	0.45%	0.43%	0.41%	0.4%	0.43%	0.45%
Research & Development	50.9M	58.16M	63.45M	78.04M	79.57M	77.38M	93.05M	101.19M	104.19M	115.38M
R&D % of Revenue	0.06%	0.06%	0.05%	0.05%	0.05%	0.06%	0.06%	0.06%	0.07%	0.07%
Other Operating Expenses	4.59M	845K	1.34M	8.29M	91.94M	27.76M	16.91M	13.88M	12.38M	21.29M
Operating Income+	79.59M	115.34M	44.8M	111M	93.76M	151.37M	197.23M	238.92M	111.53M	28.41M
Operating Margin %	0.09%	0.12%	0.04%	0.08%	0.06%	0.11%	0.13%	0.15%	0.07%	0.02%
Operating Income Growth %	0.21%	0.45%	-0.61%	1.48%	-0.16%	0.61%	0.3%	0.21%	-0.53%	-0.75%
EBITDA+	89.54M	188M	133.7M	226.7M	203.22M	270.36M	320.9M	360.04M	235.04M	168.91M
EBITDA Margin %	0.1%	0.19%	0.11%	0.15%	0.13%	0.2%	0.21%	0.23%	0.15%	0.1%
EBITDA Growth %	0.15%	1.1%	-0.29%	0.7%	-0.1%	0.33%	0.19%	0.12%	-0.35%	-0.28%
D&A (Non-Cash Add-back)	9.95M	72.67M	88.9M	115.7M	109.46M	118.99M	123.67M	121.11M	123.51M	140.5M
EBIT	84.2M	116.21M	46.33M	125.34M	114.06M	148.95M	242.66M	263.49M	132.45M	52.4M
Net Interest Income+	-23.5M	-25.78M	-34.76M	-61.88M	-43.18M	-62.28M	-43.66M	-37.68M	-34.17M	-50.59M
Interest Income	13K	24K	255K	2.8M	10.78M	9.3M	6.74M	11.92M	17.2M	20.04M
Interest Expense	23.52M	25.8M	35.02M	64.68M	53.96M	71.58M	50.4M	49.59M	51.38M	70.63M
Other Income/Expense	-18.92M	-24.93M	-33.42M	-53.59M	-33.66M	-57.85M	17.45M	-25.03M	-30.46M	-46.65M
Pretax Income+	60.67M	90.41M	11.38M	57.4M	60.1M	93.52M	214.68M	213.89M	81.07M	-18.24M
Pretax Margin %	0.07%	0.09%	0.01%	0.04%	0.04%	0.07%	0.14%	0.14%	0.05%	-0.01%
Income Tax+	53.82M	15.84M	-53.36M	-3.4M	9.9M	-40.37M	45.6M	33.34M	13.33M	-11.29M
Effective Tax Rate %	-0.06%	0.82%	5.69%	1.06%	0.84%	1.43%	0.79%	0.84%	0.84%	0.38%
Net Income+	-3.52M	74.56M	64.74M	60.8M	50.2M	133.89M	169.07M	180.55M	67.74M	-6.94M
Net Margin %	-0%	0.08%	0.05%	0.04%	0.03%	0.1%	0.11%	0.12%	0.04%	-0%
Net Income Growth %	-1.1%	22.19%	-0.13%	-0.06%	-0.17%	1.67%	0.26%	0.07%	-0.62%	-1.1%
Net Income (Continuing)	6.85M	74.56M	64.74M	60.8M	50.2M	133.89M	169.07M	180.55M	67.74M	-6.94M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.05	0.94	0.82	0.72	0.58	1.57	1.98	2.16	0.84	-0.09
EPS Growth %	-1.09%	20.75%	-0.13%	-0.12%	-0.19%	1.71%	0.26%	0.09%	-0.61%	-1.11%
EPS (Basic)	-0.05	1.00	0.83	0.73	0.59	1.58	2.00	2.18	0.87	-0.09
Diluted Shares Outstanding	73.88M	79.19M	79.12M	84.45M	86.49M	85.23M	85.48M	83.52M	80.34M	77.01M
Basic Shares Outstanding	73.88M	74.72M	78.39M	82.86M	85.64M	84.65M	84.7M	83M	78.17M	77.01M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	438.5M	495.17M	822.15M	775.08M	858.17M	1.24B	1.15B	1.16B	1.06B	1.08B
Cash & Short-Term Investments	48.13M	102.06M	174.94M	138.84M	198.91M	470.17M	513.45M	456.66M	309.1M	273.57M
Cash Only	48.13M	102.06M	174.94M	138.84M	198.91M	470.17M	513.45M	456.66M	276.4M	246.38M
Short-Term Investments	0	0	0	0	0	0	0	0	32.69M	27.19M
Accounts Receivable	132.24M	148.19M	251.8M	265.74M	275.3M	225.53M	231.83M	263.46M	259.33M	272.37M
Days Sales Outstanding	54.68	54.52	77.35	65.87	66.21	60.01	54.86	61.74	61.4	61.73
Inventory	211.43M	217.26M	296.33M	280.35M	316.05M	310.12M	317.39M	324.58M	389.61M	429.09M
Days Inventory Outstanding	236.33	227.17	248.35	179.05	204.29	217.33	193.78	201.71	216.5	215
Other Current Assets	4.07M	27.67M	99.08M	0	0	162.1M	0	31.03M	32.64M	29.65M
Total Non-Current Assets+	1.34B	1.31B	2.39B	2.33B	2.45B	2.38B	2.63B	2.73B	2.72B	2.96B
Property, Plant & Equipment	205.18M	222.37M	269.25M	300.11M	431.93M	371.16M	396.25M	459.59M	496.38M	549.76M
Fixed Asset Turnover	4.30x	4.46x	4.41x	4.91x	3.51x	3.70x	3.89x	3.39x	3.11x	2.93x
Goodwill	512.39M	510.57M	937.9M	926.48M	954.28M	932.37M	1.01B	1.04B	1.06B	1.1B
Intangible Assets	603.74M	561.17M	1.16B	1.08B	1.03B	989.44M	1.15B	1.13B	1.07B	1.21B
Long-Term Investments	0	1.63M	2.49M	5.35M	3.46M	474.83M	6.48M	567.34M	30.71M	38.3M
Other Non-Current Assets	7.97M	10.11M	13.59M	14.57M	11.18M	-463.56M	9.96M	-510.15M	27.48M	28.21M
Total Assets+	1.77B	1.81B	3.21B	3.11B	3.3B	3.62B	3.78B	3.89B	3.78B	4.04B
Asset Turnover	0.50x	0.55x	0.37x	0.47x	0.46x	0.38x	0.41x	0.40x	0.41x	0.40x
Asset Growth %	0.12%	0.02%	0.78%	-0.03%	0.06%	0.09%	0.05%	0.03%	-0.03%	0.07%
Total Current Liabilities+	139.13M	123.6M	348.91M	262.55M	331.31M	401.01M	340.02M	320.91M	306.98M	922.13M
Accounts Payable	34.77M	29.06M	93.97M	76.05M	113.09M	54.61M	61.84M	102.1M	92.33M	82.5M
Days Payables Outstanding	38.87	30.38	78.75	48.57	73.1	38.27	37.76	63.45	51.3	41.34
Short-Term Debt	14.38M	0	60M	22.5M	57.25M	146.25M	59.77M	52.75M	14.53M	607.08M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	39.16M	34.97M	110.5M	75.69M	67.13M	105.94M	105.68M	65.41M	100.84M	37.79M
Current Ratio	3.15x	4.01x	2.36x	2.95x	2.59x	3.09x	3.39x	3.62x	3.45x	1.17x
Quick Ratio	1.63x	2.25x	1.51x	1.88x	1.64x	2.31x	2.46x	2.61x	2.18x	0.71x
Cash Conversion Cycle	252.14	251.3	246.95	196.35	197.41	239.07	210.89	199.99	226.6	235.39
Total Non-Current Liabilities+	884.13M	844.69M	1.9B	1.47B	1.56B	1.7B	1.76B	1.76B	1.89B	1.57B
Long-Term Debt	700.12M	665M	1.78B	1.33B	1.3B	1.41B	1.5B	1.41B	1.49B	1.2B
Capital Lease Obligations	0	0	0	0	97.5M	88.12M	90.33M	157.42M	166.85M	166.93M
Deferred Tax Liabilities	154.89M	148.94M	65.13M	57.78M	36.55M	16.19M	45.79M	63.34M	35.32M	60.83M
Other Non-Current Liabilities	28.65M	30.75M	53.77M	80.05M	125.07M	186.73M	120.26M	138.5M	192.24M	137.04M
Total Liabilities	1.02B	968.29M	2.25B	1.73B	1.89B	2.1B	2.1B	2.09B	2.19B	2.49B
Total Debt+	714.97M	665M	1.84B	1.35B	1.46B	1.66B	1.67B	1.63B	1.68B	1.98B
Net Debt	666.84M	562.95M	1.67B	1.22B	1.26B	1.19B	1.15B	1.17B	1.41B	1.74B
Debt / Equity	0.95x	0.79x	1.91x	0.98x	1.03x	1.09x	0.99x	0.90x	1.06x	1.28x
Debt / EBITDA	7.98x	3.54x	13.77x	5.97x	7.17x	6.12x	5.19x	4.53x	7.15x	11.75x
Net Debt / EBITDA	7.45x	2.99x	12.46x	5.36x	6.19x	4.38x	3.59x	3.26x	5.98x	10.29x
Interest Coverage	3.38x	4.47x	1.28x	1.72x	1.74x	2.11x	3.91x	4.82x	2.17x	0.40x
Total Equity+	751.44M	839.67M	962.31M	1.38B	1.42B	1.51B	1.68B	1.8B	1.59B	1.55B
Equity Growth %	0.07%	0.12%	0.15%	0.43%	0.03%	0.07%	0.11%	0.07%	-0.12%	-0.03%
Book Value per Share	10.17	10.60	12.16	16.29	16.38	17.77	19.71	21.61	19.77	20.07
Total Shareholders' Equity	751.44M	839.67M	962.31M	1.38B	1.42B	1.51B	1.68B	1.8B	1.59B	1.55B
Common Stock	459K	777K	813K	880K	887K	893K	896K	905K	909K	916K
Retained Earnings	145.88M	220.44M	285.19M	348.37M	398.57M	532.26M	698.57M	879.12M	946.86M	939.91M
Treasury Stock	-367.12M	-123.05M	-121.64M	-120.61M	-119.94M	-235.14M	-234.45M	-362.86M	-647.26M	-691.41M
Accumulated OCI	-47.9M	-57.15M	-23.81M	-45.44M	-76.4M	-74.06M	-45.16M	10.27M	-15.11M	-27.57M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	94.48M	116.41M	114.54M	199.68M	231.43M	203.83M	312.43M	264.47M	139.96M	129.38M
Operating CF Margin %	0.11%	0.12%	0.1%	0.14%	0.15%	0.15%	0.2%	0.17%	0.09%	0.08%
Operating CF Growth %	0.19%	0.23%	-0.02%	0.74%	0.16%	-0.12%	0.53%	-0.15%	-0.47%	-0.08%
Net Income	6.85M	74.56M	64.74M	60.8M	50.2M	133.89M	169.07M	180.55M	67.74M	-6.94M
Depreciation & Amortization	58.86M	72.67M	88.94M	110.73M	109.46M	116.03M	119.84M	118.3M	123.51M	140.89M
Stock-Based Compensation	15.45M	17.31M	21.55M	20.78M	21.25M	19.59M	36.21M	27.73M	20.14M	24.38M
Deferred Taxes	-351K	-6.47M	-67.3M	-8.18M	-19.05M	-64.14M	-2.75M	-4.58M	-11.88M	-20.73M
Other Non-Cash Items	30.57M	-30.43M	7.93M	13.81M	84.07M	39.77M	-28.1M	-18.1M	22.02M	22.79M
Working Capital Changes	-16.9M	-11.23M	-1.32M	1.75M	-14.51M	-41.31M	18.16M	-39.42M	-81.57M	-31.01M
Change in Receivables	-16.23M	-17.52M	-89.7M	-17.02M	-9.43M	52.1M	7.26M	-33.91M	4.59M	7.4M
Change in Inventory	-3.76M	-9.58M	99K	8.3M	-43.31M	-48.35M	5.37M	-29.12M	-59.77M	-28.15M
Change in Payables	1.63M	-414K	95.32M	3.59M	14.67M	-57.51M	32.87M	17.34M	-20.23M	-2.67M
Cash from Investing+	-372.01M	-42.62M	-1.22B	-49.7M	-162.67M	-68.07M	-161.44M	-58.58M	-94.18M	-390.81M
Capital Expenditures	-33.41M	-47.33M	-43.5M	-77.74M	-69.54M	-63.89M	-48.02M	-47.09M	-66.86M	-104.42M
CapEx % of Revenue	0.04%	0.05%	0.04%	0.05%	0.05%	0.05%	0.03%	0.03%	0.04%	0.06%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-9.71M	4.48M	483K	1.33M	-64.21M	3.66M	-55K	16.05M	0	-14.08M
Cash from Financing+	258.51M	-15.12M	1.17B	-180.87M	-8.77M	121.63M	-98.23M	-251.95M	-229.93M	237.86M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	172M	1.1M	-13.93M	-41.66M	434K	-78.8M	1.77M	-24.62M	-9.43M	-9.04M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	61.07M	69.08M	71.04M	121.94M	96.9M	139.94M	264.35M	217.38M	73.09M	24.96M
FCF Margin %	0.07%	0.07%	0.06%	0.08%	0.06%	0.1%	0.17%	0.14%	0.05%	0.02%
FCF Growth %	0.65%	0.13%	0.03%	0.72%	-0.21%	0.44%	0.89%	-0.18%	-0.66%	-0.66%
FCF per Share	0.83	0.87	0.90	1.44	1.12	1.64	3.09	2.60	0.91	0.32
FCF Conversion (FCF/Net Income)	-26.85x	1.56x	1.77x	3.28x	4.61x	1.52x	1.85x	1.46x	2.07x	-18.63x
Interest Paid	12.7K	57.2K	32.3K	58.3K	48.9K	47.3K	43.2M	42.2M	44.3M	64.4M
Taxes Paid	21.3K	4.3K	14.6K	10.4K	16.2K	29.8K	49.5M	35.9M	23.6M	22.7M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-0.48%	9.37%	7.19%	5.2%	3.6%	9.13%	10.57%	10.35%	3.99%	-0.44%
Return on Invested Capital (ROIC)	4.45%	6.13%	1.67%	3.19%	2.67%	4.22%	5.34%	6.16%	2.8%	0.68%
Gross Margin	63.01%	64.81%	63.35%	61.19%	62.79%	62.03%	61.24%	62.29%	57.39%	54.77%
Net Margin	-0.4%	7.52%	5.45%	4.13%	3.31%	9.76%	10.96%	11.59%	4.39%	-0.43%
Debt / Equity	0.95x	0.79x	1.91x	0.98x	1.03x	1.09x	0.99x	0.90x	1.06x	1.28x
Interest Coverage	3.38x	4.47x	1.28x	1.72x	1.74x	2.11x	3.91x	4.82x	2.17x	0.40x
FCF Conversion	-26.85x	1.56x	1.77x	3.28x	4.61x	1.52x	1.85x	1.46x	2.07x	-18.63x
Revenue Growth	-4.91%	12.39%	19.77%	23.92%	3.06%	-9.6%	12.43%	0.99%	-1.03%	4.47%

Revenue by Segment

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2024
Codman Specialty Surgical	-	-	-	720.3M	963.93M	996.21M	894.83M	1.03B	1.02B	1.14B
Codman Specialty Surgical Growth	-	-	-	-	33.82%	3.35%	-10.18%	14.57%	-0.55%	12.17%
Tissue Technologies	-	-	-	-	-	-	-	517.22M	538.1M	466.89M
Tissue Technologies Growth	-	-	-	-	-	-	-	-	4.04%	-13.23%
Orthopedics and Tissue Technologies	-	-	359.55M	467.94M	508.51M	521.35M	477.04M	-	-	-
Orthopedics and Tissue Technologies Growth	-	-	-	30.14%	8.67%	2.52%	-8.50%	-	-	-
Specialty Surgical Solutions	-	-	632.52M	-	-	-	-	-	-	-
Specialty Surgical Solutions Growth	-	-	-	-	-	-	-	-	-	-
U S Neurosurgery	244.6M	586.92M	-	-	-	-	-	-	-	-
U S Neurosurgery Growth	-	139.95%	-	-	-	-	-	-	-	-
U S Instruments	157.82M	295.82M	-	-	-	-	-	-	-	-
U S Instruments Growth	-	87.44%	-	-	-	-	-	-	-	-
International	211.14M	-	-	-	-	-	-	-	-	-
International Growth	-	-	-	-	-	-	-	-	-	-
U S Spine And Other	171.36M	-	-	-	-	-	-	-	-	-
U S Spine And Other Growth	-	-	-	-	-	-	-	-	-	-
U S Extremities	143.38M	-	-	-	-	-	-	-	-	-
U S Extremities Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2024
UNITED STATES	714.04M	680.82M	765.61M	894.26M	1.05B	1.08B	971.98M	1.09B	1.13B	1.19B
UNITED STATES Growth	-	-4.65%	12.45%	16.80%	16.96%	3.01%	-9.78%	12.09%	3.42%	5.85%
Asia Pacific	-	-	-	-	144.25M	157.39M	157.17M	182.03M	176.48M	176.61M
Asia Pacific Growth	-	-	-	-	-	9.11%	-0.14%	15.82%	-3.05%	0.08%
Europe	105.7M	103.06M	120.59M	150.15M	201.35M	197.47M	172.69M	191.33M	170.9M	158.5M
Europe Growth	-	-2.50%	17.01%	24.51%	34.10%	-1.93%	-12.55%	10.79%	-10.67%	-7.26%
Rest Of The World	-	-	-	-	-	-	-	-	-	82.74M
Rest Of The World Growth	-	-	-	-	-	-	-	-	-	-
Rest Of World	108.57M	98.85M	105.88M	143.83M	80.95M	85.32M	70.03M	79.56M	83.48M	-
Rest Of World Growth	-	-8.95%	7.11%	35.84%	-43.72%	5.40%	-17.92%	13.61%	4.92%	-

Frequently Asked Questions

Growth & Financials

Integra LifeSciences Holdings Corporation (IART) reported $1.64B in revenue for fiscal year 2024. This represents a 111% increase from $780.1M in 2011.

Integra LifeSciences Holdings Corporation (IART) grew revenue by 4.5% over the past year. Growth has been modest.

Integra LifeSciences Holdings Corporation (IART) reported a net loss of $495.3M for fiscal year 2024.

Dividend & Returns

Integra LifeSciences Holdings Corporation (IART) has a return on equity (ROE) of -0.4%. Negative ROE indicates the company is unprofitable.

Integra LifeSciences Holdings Corporation (IART) had negative free cash flow of $14.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Integra LifeSciences Holdings Corporation (IART) 10-Year Financial Performance & Capital Metrics

IART • • Industrial / General

HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems

Revenue $1.61B +4.5%
EBITDA $169M -28.1%
Net Income -$7M -110.3%
EPS (Diluted) -0.09 -110.7%
Gross Margin 54.77% -4.6%
EBITDA Margin 10.49% -31.2%
Operating Margin 1.76% -75.6%
Net Margin -0.43% -109.8%
ROE -0.44% -111.1%
ROIC 0.68% -75.8%
Debt/Equity 1.28 +21.3%
Interest Coverage 0.40 -81.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 4.1% through buybacks
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak 3Y average ROE of 4.6%
✗Weak Piotroski F-Score: 3/9
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.66%

5Y1.2%

3Y1.45%

TTM4.99%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-7469.3%

EPS CAGR

10Y-

5Y-

3Y-

TTM-6928.63%

ROCE

10Y Avg4.29%

5Y Avg4.33%

3Y Avg3.61%

Latest0.86%

Peer Comparison

Surgical Energy & Ablation Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BDMDBaird Medical Investment Holdings Limited	45.91M	1.25	2.55	17.74%	33.62%	33%	0.53
IVFINVO Fertility, Inc.	12.29M	0.81	-0.03	116.25%	-417.01%	-495.09%	0.78
AEMDAethlon Medical, Inc.	2.64M	2.71	-0.03			-0.2%	0.13
HYPDHyperion DeFi, Inc.	27.38M	3.35	-0.06	14.14%	-73.86%	-36.05%
NAOVNanoVibronix, Inc.	1.59M	1.46	-0.11	12.05%	-133.04%	-8.41%	0.19
ALURAllurion Technologies Inc.	23.21M	1.89	-0.16	-39.94%	-251.56%
RBOTVicarious Surgical Inc.	18.48M	2.86	-0.27			-380.42%	0.30
TELATELA Bio, Inc.	44.09M	0.99	-0.74	18.56%	-50.61%	-25.05%	1.51

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	882.73M	992.08M	1.19B	1.47B	1.52B	1.37B	1.54B	1.56B	1.54B	1.61B
Revenue Growth %	-0.05%	0.12%	0.2%	0.24%	0.03%	-0.1%	0.12%	0.01%	-0.01%	0.04%
Cost of Goods Sold+	326.54M	349.09M	435.51M	571.5M	564.68M	520.83M	597.81M	587.36M	656.84M	728.47M
COGS % of Revenue	0.37%	0.35%	0.37%	0.39%	0.37%	0.38%	0.39%	0.38%	0.43%	0.45%
Gross Profit+	556.19M	642.99M	752.73M	900.95M	952.88M	851.03M	944.64M	970.31M	884.74M	882.06M
Gross Margin %	0.63%	0.65%	0.63%	0.61%	0.63%	0.62%	0.61%	0.62%	0.57%	0.55%
Gross Profit Growth %	-0.03%	0.16%	0.17%	0.2%	0.06%	-0.11%	0.11%	0.03%	-0.09%	-0%
Operating Expenses+	476.61M	527.65M	707.92M	789.95M	859.12M	699.66M	747.41M	731.39M	773.21M	853.65M
OpEx % of Revenue	0.54%	0.53%	0.6%	0.54%	0.57%	0.51%	0.48%	0.47%	0.5%	0.53%
Selling, General & Admin	415.76M	455.63M	624.1M	690.75M	687.6M	594.53M	637.45M	616.32M	656.64M	716.98M
SG&A % of Revenue	0.47%	0.46%	0.53%	0.47%	0.45%	0.43%	0.41%	0.4%	0.43%	0.45%
Research & Development	50.9M	58.16M	63.45M	78.04M	79.57M	77.38M	93.05M	101.19M	104.19M	115.38M
R&D % of Revenue	0.06%	0.06%	0.05%	0.05%	0.05%	0.06%	0.06%	0.06%	0.07%	0.07%
Other Operating Expenses	4.59M	845K	1.34M	8.29M	91.94M	27.76M	16.91M	13.88M	12.38M	21.29M
Operating Income+	79.59M	115.34M	44.8M	111M	93.76M	151.37M	197.23M	238.92M	111.53M	28.41M
Operating Margin %	0.09%	0.12%	0.04%	0.08%	0.06%	0.11%	0.13%	0.15%	0.07%	0.02%
Operating Income Growth %	0.21%	0.45%	-0.61%	1.48%	-0.16%	0.61%	0.3%	0.21%	-0.53%	-0.75%
EBITDA+	89.54M	188M	133.7M	226.7M	203.22M	270.36M	320.9M	360.04M	235.04M	168.91M
EBITDA Margin %	0.1%	0.19%	0.11%	0.15%	0.13%	0.2%	0.21%	0.23%	0.15%	0.1%
EBITDA Growth %	0.15%	1.1%	-0.29%	0.7%	-0.1%	0.33%	0.19%	0.12%	-0.35%	-0.28%
D&A (Non-Cash Add-back)	9.95M	72.67M	88.9M	115.7M	109.46M	118.99M	123.67M	121.11M	123.51M	140.5M
EBIT	84.2M	116.21M	46.33M	125.34M	114.06M	148.95M	242.66M	263.49M	132.45M	52.4M
Net Interest Income+	-23.5M	-25.78M	-34.76M	-61.88M	-43.18M	-62.28M	-43.66M	-37.68M	-34.17M	-50.59M
Interest Income	13K	24K	255K	2.8M	10.78M	9.3M	6.74M	11.92M	17.2M	20.04M
Interest Expense	23.52M	25.8M	35.02M	64.68M	53.96M	71.58M	50.4M	49.59M	51.38M	70.63M
Other Income/Expense	-18.92M	-24.93M	-33.42M	-53.59M	-33.66M	-57.85M	17.45M	-25.03M	-30.46M	-46.65M
Pretax Income+	60.67M	90.41M	11.38M	57.4M	60.1M	93.52M	214.68M	213.89M	81.07M	-18.24M
Pretax Margin %	0.07%	0.09%	0.01%	0.04%	0.04%	0.07%	0.14%	0.14%	0.05%	-0.01%
Income Tax+	53.82M	15.84M	-53.36M	-3.4M	9.9M	-40.37M	45.6M	33.34M	13.33M	-11.29M
Effective Tax Rate %	-0.06%	0.82%	5.69%	1.06%	0.84%	1.43%	0.79%	0.84%	0.84%	0.38%
Net Income+	-3.52M	74.56M	64.74M	60.8M	50.2M	133.89M	169.07M	180.55M	67.74M	-6.94M
Net Margin %	-0%	0.08%	0.05%	0.04%	0.03%	0.1%	0.11%	0.12%	0.04%	-0%
Net Income Growth %	-1.1%	22.19%	-0.13%	-0.06%	-0.17%	1.67%	0.26%	0.07%	-0.62%	-1.1%
Net Income (Continuing)	6.85M	74.56M	64.74M	60.8M	50.2M	133.89M	169.07M	180.55M	67.74M	-6.94M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.05	0.94	0.82	0.72	0.58	1.57	1.98	2.16	0.84	-0.09
EPS Growth %	-1.09%	20.75%	-0.13%	-0.12%	-0.19%	1.71%	0.26%	0.09%	-0.61%	-1.11%
EPS (Basic)	-0.05	1.00	0.83	0.73	0.59	1.58	2.00	2.18	0.87	-0.09
Diluted Shares Outstanding	73.88M	79.19M	79.12M	84.45M	86.49M	85.23M	85.48M	83.52M	80.34M	77.01M
Basic Shares Outstanding	73.88M	74.72M	78.39M	82.86M	85.64M	84.65M	84.7M	83M	78.17M	77.01M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	438.5M	495.17M	822.15M	775.08M	858.17M	1.24B	1.15B	1.16B	1.06B	1.08B
Cash & Short-Term Investments	48.13M	102.06M	174.94M	138.84M	198.91M	470.17M	513.45M	456.66M	309.1M	273.57M
Cash Only	48.13M	102.06M	174.94M	138.84M	198.91M	470.17M	513.45M	456.66M	276.4M	246.38M
Short-Term Investments	0	0	0	0	0	0	0	0	32.69M	27.19M
Accounts Receivable	132.24M	148.19M	251.8M	265.74M	275.3M	225.53M	231.83M	263.46M	259.33M	272.37M
Days Sales Outstanding	54.68	54.52	77.35	65.87	66.21	60.01	54.86	61.74	61.4	61.73
Inventory	211.43M	217.26M	296.33M	280.35M	316.05M	310.12M	317.39M	324.58M	389.61M	429.09M
Days Inventory Outstanding	236.33	227.17	248.35	179.05	204.29	217.33	193.78	201.71	216.5	215
Other Current Assets	4.07M	27.67M	99.08M	0	0	162.1M	0	31.03M	32.64M	29.65M
Total Non-Current Assets+	1.34B	1.31B	2.39B	2.33B	2.45B	2.38B	2.63B	2.73B	2.72B	2.96B
Property, Plant & Equipment	205.18M	222.37M	269.25M	300.11M	431.93M	371.16M	396.25M	459.59M	496.38M	549.76M
Fixed Asset Turnover	4.30x	4.46x	4.41x	4.91x	3.51x	3.70x	3.89x	3.39x	3.11x	2.93x
Goodwill	512.39M	510.57M	937.9M	926.48M	954.28M	932.37M	1.01B	1.04B	1.06B	1.1B
Intangible Assets	603.74M	561.17M	1.16B	1.08B	1.03B	989.44M	1.15B	1.13B	1.07B	1.21B
Long-Term Investments	0	1.63M	2.49M	5.35M	3.46M	474.83M	6.48M	567.34M	30.71M	38.3M
Other Non-Current Assets	7.97M	10.11M	13.59M	14.57M	11.18M	-463.56M	9.96M	-510.15M	27.48M	28.21M
Total Assets+	1.77B	1.81B	3.21B	3.11B	3.3B	3.62B	3.78B	3.89B	3.78B	4.04B
Asset Turnover	0.50x	0.55x	0.37x	0.47x	0.46x	0.38x	0.41x	0.40x	0.41x	0.40x
Asset Growth %	0.12%	0.02%	0.78%	-0.03%	0.06%	0.09%	0.05%	0.03%	-0.03%	0.07%
Total Current Liabilities+	139.13M	123.6M	348.91M	262.55M	331.31M	401.01M	340.02M	320.91M	306.98M	922.13M
Accounts Payable	34.77M	29.06M	93.97M	76.05M	113.09M	54.61M	61.84M	102.1M	92.33M	82.5M
Days Payables Outstanding	38.87	30.38	78.75	48.57	73.1	38.27	37.76	63.45	51.3	41.34
Short-Term Debt	14.38M	0	60M	22.5M	57.25M	146.25M	59.77M	52.75M	14.53M	607.08M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	39.16M	34.97M	110.5M	75.69M	67.13M	105.94M	105.68M	65.41M	100.84M	37.79M
Current Ratio	3.15x	4.01x	2.36x	2.95x	2.59x	3.09x	3.39x	3.62x	3.45x	1.17x
Quick Ratio	1.63x	2.25x	1.51x	1.88x	1.64x	2.31x	2.46x	2.61x	2.18x	0.71x
Cash Conversion Cycle	252.14	251.3	246.95	196.35	197.41	239.07	210.89	199.99	226.6	235.39
Total Non-Current Liabilities+	884.13M	844.69M	1.9B	1.47B	1.56B	1.7B	1.76B	1.76B	1.89B	1.57B
Long-Term Debt	700.12M	665M	1.78B	1.33B	1.3B	1.41B	1.5B	1.41B	1.49B	1.2B
Capital Lease Obligations	0	0	0	0	97.5M	88.12M	90.33M	157.42M	166.85M	166.93M
Deferred Tax Liabilities	154.89M	148.94M	65.13M	57.78M	36.55M	16.19M	45.79M	63.34M	35.32M	60.83M
Other Non-Current Liabilities	28.65M	30.75M	53.77M	80.05M	125.07M	186.73M	120.26M	138.5M	192.24M	137.04M
Total Liabilities	1.02B	968.29M	2.25B	1.73B	1.89B	2.1B	2.1B	2.09B	2.19B	2.49B
Total Debt+	714.97M	665M	1.84B	1.35B	1.46B	1.66B	1.67B	1.63B	1.68B	1.98B
Net Debt	666.84M	562.95M	1.67B	1.22B	1.26B	1.19B	1.15B	1.17B	1.41B	1.74B
Debt / Equity	0.95x	0.79x	1.91x	0.98x	1.03x	1.09x	0.99x	0.90x	1.06x	1.28x
Debt / EBITDA	7.98x	3.54x	13.77x	5.97x	7.17x	6.12x	5.19x	4.53x	7.15x	11.75x
Net Debt / EBITDA	7.45x	2.99x	12.46x	5.36x	6.19x	4.38x	3.59x	3.26x	5.98x	10.29x
Interest Coverage	3.38x	4.47x	1.28x	1.72x	1.74x	2.11x	3.91x	4.82x	2.17x	0.40x
Total Equity+	751.44M	839.67M	962.31M	1.38B	1.42B	1.51B	1.68B	1.8B	1.59B	1.55B
Equity Growth %	0.07%	0.12%	0.15%	0.43%	0.03%	0.07%	0.11%	0.07%	-0.12%	-0.03%
Book Value per Share	10.17	10.60	12.16	16.29	16.38	17.77	19.71	21.61	19.77	20.07
Total Shareholders' Equity	751.44M	839.67M	962.31M	1.38B	1.42B	1.51B	1.68B	1.8B	1.59B	1.55B
Common Stock	459K	777K	813K	880K	887K	893K	896K	905K	909K	916K
Retained Earnings	145.88M	220.44M	285.19M	348.37M	398.57M	532.26M	698.57M	879.12M	946.86M	939.91M
Treasury Stock	-367.12M	-123.05M	-121.64M	-120.61M	-119.94M	-235.14M	-234.45M	-362.86M	-647.26M	-691.41M
Accumulated OCI	-47.9M	-57.15M	-23.81M	-45.44M	-76.4M	-74.06M	-45.16M	10.27M	-15.11M	-27.57M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	94.48M	116.41M	114.54M	199.68M	231.43M	203.83M	312.43M	264.47M	139.96M	129.38M
Operating CF Margin %	0.11%	0.12%	0.1%	0.14%	0.15%	0.15%	0.2%	0.17%	0.09%	0.08%
Operating CF Growth %	0.19%	0.23%	-0.02%	0.74%	0.16%	-0.12%	0.53%	-0.15%	-0.47%	-0.08%
Net Income	6.85M	74.56M	64.74M	60.8M	50.2M	133.89M	169.07M	180.55M	67.74M	-6.94M
Depreciation & Amortization	58.86M	72.67M	88.94M	110.73M	109.46M	116.03M	119.84M	118.3M	123.51M	140.89M
Stock-Based Compensation	15.45M	17.31M	21.55M	20.78M	21.25M	19.59M	36.21M	27.73M	20.14M	24.38M
Deferred Taxes	-351K	-6.47M	-67.3M	-8.18M	-19.05M	-64.14M	-2.75M	-4.58M	-11.88M	-20.73M
Other Non-Cash Items	30.57M	-30.43M	7.93M	13.81M	84.07M	39.77M	-28.1M	-18.1M	22.02M	22.79M
Working Capital Changes	-16.9M	-11.23M	-1.32M	1.75M	-14.51M	-41.31M	18.16M	-39.42M	-81.57M	-31.01M
Change in Receivables	-16.23M	-17.52M	-89.7M	-17.02M	-9.43M	52.1M	7.26M	-33.91M	4.59M	7.4M
Change in Inventory	-3.76M	-9.58M	99K	8.3M	-43.31M	-48.35M	5.37M	-29.12M	-59.77M	-28.15M
Change in Payables	1.63M	-414K	95.32M	3.59M	14.67M	-57.51M	32.87M	17.34M	-20.23M	-2.67M
Cash from Investing+	-372.01M	-42.62M	-1.22B	-49.7M	-162.67M	-68.07M	-161.44M	-58.58M	-94.18M	-390.81M
Capital Expenditures	-33.41M	-47.33M	-43.5M	-77.74M	-69.54M	-63.89M	-48.02M	-47.09M	-66.86M	-104.42M
CapEx % of Revenue	0.04%	0.05%	0.04%	0.05%	0.05%	0.05%	0.03%	0.03%	0.04%	0.06%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-9.71M	4.48M	483K	1.33M	-64.21M	3.66M	-55K	16.05M	0	-14.08M
Cash from Financing+	258.51M	-15.12M	1.17B	-180.87M	-8.77M	121.63M	-98.23M	-251.95M	-229.93M	237.86M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	172M	1.1M	-13.93M	-41.66M	434K	-78.8M	1.77M	-24.62M	-9.43M	-9.04M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	61.07M	69.08M	71.04M	121.94M	96.9M	139.94M	264.35M	217.38M	73.09M	24.96M
FCF Margin %	0.07%	0.07%	0.06%	0.08%	0.06%	0.1%	0.17%	0.14%	0.05%	0.02%
FCF Growth %	0.65%	0.13%	0.03%	0.72%	-0.21%	0.44%	0.89%	-0.18%	-0.66%	-0.66%
FCF per Share	0.83	0.87	0.90	1.44	1.12	1.64	3.09	2.60	0.91	0.32
FCF Conversion (FCF/Net Income)	-26.85x	1.56x	1.77x	3.28x	4.61x	1.52x	1.85x	1.46x	2.07x	-18.63x
Interest Paid	12.7K	57.2K	32.3K	58.3K	48.9K	47.3K	43.2M	42.2M	44.3M	64.4M
Taxes Paid	21.3K	4.3K	14.6K	10.4K	16.2K	29.8K	49.5M	35.9M	23.6M	22.7M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-0.48%	9.37%	7.19%	5.2%	3.6%	9.13%	10.57%	10.35%	3.99%	-0.44%
Return on Invested Capital (ROIC)	4.45%	6.13%	1.67%	3.19%	2.67%	4.22%	5.34%	6.16%	2.8%	0.68%
Gross Margin	63.01%	64.81%	63.35%	61.19%	62.79%	62.03%	61.24%	62.29%	57.39%	54.77%
Net Margin	-0.4%	7.52%	5.45%	4.13%	3.31%	9.76%	10.96%	11.59%	4.39%	-0.43%
Debt / Equity	0.95x	0.79x	1.91x	0.98x	1.03x	1.09x	0.99x	0.90x	1.06x	1.28x
Interest Coverage	3.38x	4.47x	1.28x	1.72x	1.74x	2.11x	3.91x	4.82x	2.17x	0.40x
FCF Conversion	-26.85x	1.56x	1.77x	3.28x	4.61x	1.52x	1.85x	1.46x	2.07x	-18.63x
Revenue Growth	-4.91%	12.39%	19.77%	23.92%	3.06%	-9.6%	12.43%	0.99%	-1.03%	4.47%

Revenue by Segment

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2024
Codman Specialty Surgical	-	-	-	720.3M	963.93M	996.21M	894.83M	1.03B	1.02B	1.14B
Codman Specialty Surgical Growth	-	-	-	-	33.82%	3.35%	-10.18%	14.57%	-0.55%	12.17%
Tissue Technologies	-	-	-	-	-	-	-	517.22M	538.1M	466.89M
Tissue Technologies Growth	-	-	-	-	-	-	-	-	4.04%	-13.23%
Orthopedics and Tissue Technologies	-	-	359.55M	467.94M	508.51M	521.35M	477.04M	-	-	-
Orthopedics and Tissue Technologies Growth	-	-	-	30.14%	8.67%	2.52%	-8.50%	-	-	-
Specialty Surgical Solutions	-	-	632.52M	-	-	-	-	-	-	-
Specialty Surgical Solutions Growth	-	-	-	-	-	-	-	-	-	-
U S Neurosurgery	244.6M	586.92M	-	-	-	-	-	-	-	-
U S Neurosurgery Growth	-	139.95%	-	-	-	-	-	-	-	-
U S Instruments	157.82M	295.82M	-	-	-	-	-	-	-	-
U S Instruments Growth	-	87.44%	-	-	-	-	-	-	-	-
International	211.14M	-	-	-	-	-	-	-	-	-
International Growth	-	-	-	-	-	-	-	-	-	-
U S Spine And Other	171.36M	-	-	-	-	-	-	-	-	-
U S Spine And Other Growth	-	-	-	-	-	-	-	-	-	-
U S Extremities	143.38M	-	-	-	-	-	-	-	-	-
U S Extremities Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2024
UNITED STATES	714.04M	680.82M	765.61M	894.26M	1.05B	1.08B	971.98M	1.09B	1.13B	1.19B
UNITED STATES Growth	-	-4.65%	12.45%	16.80%	16.96%	3.01%	-9.78%	12.09%	3.42%	5.85%
Asia Pacific	-	-	-	-	144.25M	157.39M	157.17M	182.03M	176.48M	176.61M
Asia Pacific Growth	-	-	-	-	-	9.11%	-0.14%	15.82%	-3.05%	0.08%
Europe	105.7M	103.06M	120.59M	150.15M	201.35M	197.47M	172.69M	191.33M	170.9M	158.5M
Europe Growth	-	-2.50%	17.01%	24.51%	34.10%	-1.93%	-12.55%	10.79%	-10.67%	-7.26%
Rest Of The World	-	-	-	-	-	-	-	-	-	82.74M
Rest Of The World Growth	-	-	-	-	-	-	-	-	-	-
Rest Of World	108.57M	98.85M	105.88M	143.83M	80.95M	85.32M	70.03M	79.56M	83.48M	-
Rest Of World Growth	-	-8.95%	7.11%	35.84%	-43.72%	5.40%	-17.92%	13.61%	4.92%	-

Frequently Asked Questions

Growth & Financials

Integra LifeSciences Holdings Corporation (IART) reported $1.64B in revenue for fiscal year 2024. This represents a 111% increase from $780.1M in 2011.

Integra LifeSciences Holdings Corporation (IART) grew revenue by 4.5% over the past year. Growth has been modest.

Integra LifeSciences Holdings Corporation (IART) reported a net loss of $495.3M for fiscal year 2024.

Dividend & Returns

Integra LifeSciences Holdings Corporation (IART) has a return on equity (ROE) of -0.4%. Negative ROE indicates the company is unprofitable.

Integra LifeSciences Holdings Corporation (IART) had negative free cash flow of $14.5M in fiscal year 2024, likely due to heavy capital investments.